|  | Webinar: The New Role of Social Networks in Patient Education Thursday, August 4, 2022 | 2:00pm ET / 11:00am PT Whether developing a drug for a new indication, preparing for the launch of a new drug, or building awareness of an existing therapy, one thing is clear; you have to break through the noise and engage patients directly at every stage of the process to be successful. Join this webinar for insights into the increasingly important role social networks play in patient education and engagement. Register now. |
|---|
Featured Story | By Nick Paul Taylor Johnson & Johnson’s attempt to switch physicians from intravenous to subcutaneous Darzalex is almost complete. Having won FDA approval for Darzalex Faspro in May 2020, J&J has converted 85% of its U.S. business to the subcutaneous formulation of the cancer treatment. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor ARS Pharmaceuticals is backing onto Nasdaq through a reverse merger with Silverback Therapeutics to bag cash to commercialize an epinephrine nasal spray and win market share from the incumbent EpiPen. read more By Nick Paul Taylor Avadel Pharmaceuticals has taken a step toward challenging Jazz Pharmaceuticals for the narcolepsy market. The FDA granted tentative approval to the company’s extended-release rival to Xyrem, leaving a patent as the last barrier between it and the market. read more By Nick Paul Taylor What factors determine the effectiveness of drug delivery nanoparticles in different settings? The lack of a good way to answer that question has potentially held back a technology with the potential to improve the risk-benefit profile of cancer therapies. Recognizing that, researchers at Massachusetts Institute of Technology have run a large-scale screen to show how cancer cells respond to nanoparticles. read more By Fraiser Kansteiner After developing the massively successful COVID shot, Comirnaty, Pfizer and BioNTech are responding to CureVac's litigation, saying they are facing what they call “threats of a groundless patent infringement suit by a company, CureVac, who has been unable to bring to market any product to help in the fight against COVID-19.” read more By Teresa Carey This week on "The Top Line," we discuss the significant increase in layoffs and what that means for the biotech industry. Also under discussion is our special report on the top 10 companies by generic drugs sales. read more Resources Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
